AMBER THERAPEUTICS HOLDINGS LIMITED
Get an alert when AMBER THERAPEUTICS HOLDINGS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-12-31 (in 7mo)
Last made up 2025-12-17
Watchouts
Cash
£14M
+439.2% highest in 4 filed years
Net assets
£16M
+788.9% highest in 4 filed years
Employees
24
+60% highest in 4 filed years
Profit before tax
—
Period ending 2024-12-31
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Net assets
6-year trend · vs Health Care median
Accounts
6-year trend · latest reflected 2024-12-31
| Metric | Trend | 2021-12-31 | 2022-01-01 | 2022-12-31 | 2023-01-01 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Turnover | — | — | — | — | — | — | |
| Operating profit | — | — | — | — | — | — | |
| Profit before tax | — | — | — | — | — | — | |
| Net profit | — | — | -£264,156 | — | -£2,589,565 | -£8,142,201 | |
| Cash | £498,684 | — | £194,670 | — | £2,531,913 | £13,651,887 | |
| Total assets less current liabilities | — | — | £234,952 | — | -£1,540,714 | £17,091,897 | |
| Net assets | £499,108 | — | £234,952 | — | -£2,354,613 | £16,221,639 | |
| Equity | £499,108 | £499,108 | £234,952 | £234,952 | -£2,354,613 | £16,221,639 | |
| Average employees | 2 | — | 2 | — | 15 | 24 | |
| Wages | — | — | — | — | — | — | |
| Directors' remuneration | — | — | — | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
+439.2%
£2,531,913 £13,651,887
highest in 4 filed years
-
Net assets
+788.9%
-£2,354,613 £16,221,639
highest in 4 filed years
-
Employees
+60%
15 24
highest in 4 filed years
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2021-12-31 | 2022-01-01 | 2022-12-31 | 2023-01-01 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Current ratio | — | — | — | — | 0.40x | 18.91x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- AMBER THERAPEUTICS HOLDINGS LIMITED 2024-07-11 → present
- AMBER THERAPEUTICS LTD 2020-12-18 → 2024-07-11
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Consolidated group
- Abridged
- Yes — abridged accounts (limited disclosure)
- Auditor
- James Cowper Kreston Audit
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“During the year the Company successfully signed a Series A Fundraise for a total of £80.9m of which £70m will be received in three tranches, and £10.9m relates to the conversion of convertible loan notes held by the Company. Tranche 1 has been successfully completed with the Company issuing 3,926,701 Series A shares for a total consideration of $18,567,259 and £146,199. On completion of Tranche 1, the convertible loan notes of £10,900,000 converted into 1,047,121 Series A shares and 2,257,853 Series A 1 shares at par. In addition following the year end the Company successfully completed Tranche 2 of the Series A funding with the Company issuing 3,361,257 Series A shares for a total consideration of $15,903,801 and £116,961.”
Group structure
- AMBER THERAPEUTICS HOLDINGS LIMITED · parent
- Amber Therapeutics Limited 100%
- Bioinduction Limited 100%
- Amber Therapeutics PTY Limited 100%
- Amber Therapeutics Ireland Limited 100%
- Amber Therapeutics Inc 100%
- Amber Therapeutics Canada Limited 100%
Significant events
- “During the year the Company successfully signed a Series A Fundraise for a total of £80.9m of which £70m will be received in three tranches, and £10.9m relates to the conversion of convertible loan notes held by the Company.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 2 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| AMERSON, David Rogers | Director | 2025-04-15 | Dec 1962 | American |
| BUTLER, Caroline | Director | 2024-05-23 | Feb 1980 | Irish |
| CHAMAS, Liliane, Doctor | Director | 2021-06-18 | Oct 1986 | British,Canadian |
| CHU, Yen-Min Kevin | Director | 2024-05-23 | Feb 1989 | Canadian |
| CRAWLEY, Aidan Harold Winston | Director | 2020-12-18 | Oct 1983 | British |
| LE, Tiffany | Director | 2024-05-23 | Jun 1990 | American |
Show 2 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DENISON, Tim | Director | 2021-06-18 | 2024-05-23 |
| GLENN, Jonathan Martin | Director | 2023-12-01 | 2024-04-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Oxford Science Enterprises Holdings Ii Limited | Corporate entity | Shares 25–50%, Voting 25–50% | 2025-05-28 | Active |
| Oxford Science Enterprises Plc | Corporate entity | Shares 25–50%, Voting 25–50% | 2024-05-23 | Ceased 2025-05-28 |
| Aidan Harold Winston Crawley | Individual | Shares 75–100%, Voting 75–100%, Appoints directors | 2020-12-18 | Ceased 2021-06-18 |
Filing timeline
Last 20 of 62 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-12-24 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-12-23 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-12-23 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2025-12-18 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2025-09-05 | AA | accounts | Accounts with accounts type group | |
| 2025-09-04 | SH01 | capital | Capital allotment shares | |
| 2025-09-04 | SH01 | capital | Capital allotment shares | |
| 2025-06-17 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-06-16 | RP04SH01 | capital | Second filing capital allotment shares | |
| 2025-06-16 | RP04SH01 | capital | Second filing capital allotment shares | |
| 2025-06-16 | SH01 | capital | Capital allotment shares | |
| 2025-04-16 | SH01 | capital | Capital allotment shares | |
| 2025-04-16 | SH01 | capital | Capital allotment shares | |
| 2025-04-15 | AP01 | officers | Appoint person director company with name date | |
| 2025-02-04 | SH01 | capital | Capital allotment shares | |
| 2025-02-03 | RP04SH01 | capital | Second filing capital allotment shares | |
| 2025-01-29 | SH01 | capital | Capital allotment shares | |
| 2024-12-26 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-11-12 | SH01 | capital | Capital allotment shares | |
| 2024-09-18 | AA | accounts | Accounts with accounts type group |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 11
- Capital events
- 11
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.